Legato Capital Management LLC Buys 22,829 Shares of Xenon Pharmaceuticals Inc. $XENE

Legato Capital Management LLC raised its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 160.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 37,038 shares of the biopharmaceutical company’s stock after purchasing an additional 22,829 shares during the quarter. Legato Capital Management LLC’s holdings in Xenon Pharmaceuticals were worth $1,660,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Neo Ivy Capital Management bought a new stake in Xenon Pharmaceuticals in the 3rd quarter valued at $2,001,000. JPMorgan Chase & Co. increased its holdings in shares of Xenon Pharmaceuticals by 11.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock worth $56,171,000 after buying an additional 142,452 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth about $5,342,000. HighVista Strategies LLC increased its holdings in shares of Xenon Pharmaceuticals by 80.2% in the 3rd quarter. HighVista Strategies LLC now owns 82,190 shares of the biopharmaceutical company’s stock worth $3,300,000 after buying an additional 36,570 shares during the last quarter. Finally, Peregrine Capital Management LLC bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth about $7,837,000. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $54.17 on Friday. The company has a market cap of $5.24 billion, a P/E ratio of -11.53 and a beta of 0.65. Xenon Pharmaceuticals Inc. has a 1 year low of $28.19 and a 1 year high of $63.95. The firm has a 50-day simple moving average of $56.15 and a two-hundred day simple moving average of $47.56.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.17). During the same quarter in the prior year, the company posted ($0.83) earnings per share. As a group, equities research analysts expect that Xenon Pharmaceuticals Inc. will post -4.88 EPS for the current year.

Wall Street Analysts Forecast Growth

XENE has been the topic of a number of research reports. Jefferies Financial Group set a $100.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Wells Fargo & Company restated an “overweight” rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. JPMorgan Chase & Co. boosted their target price on shares of Xenon Pharmaceuticals from $77.00 to $80.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Finally, Needham & Company LLC reduced their target price on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $77.07.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, insider Christopher John Kenney sold 1,410 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $77,874.30. Following the completion of the sale, the insider owned 7,069 shares of the company’s stock, valued at $390,420.87. This trade represents a 16.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ian Mortimer sold 7,308 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $403,620.84. Following the completion of the sale, the chief executive officer directly owned 19,923 shares of the company’s stock, valued at approximately $1,100,347.29. The trade was a 26.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 296,707 shares of company stock valued at $17,845,365 over the last 90 days. Insiders own 4.07% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.